Lifeboat Foundation

Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm

Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.

“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”

Continue reading “Bioquark Inc. and SC21 Biotech to Collaborate on Novel Cellular Therapies for Long Term HIV Control” »

Rare breeds of chickens could soon come from entirely different types of hens. The University of Edinburgh’s Roslin Institute with help from US biotechnology company Recombinetics used gene editing techniques to create surrogate hens that grow up to produce eggs with all the genetic information of different breeds.

We’ve seen gene editing and transfer techniques used to create better yeast, bigger trees and even glowing pigs, among numerous other examples, but this is believed to be the first gene-edited bird to come out of Europe.

The team used a gene editing tool called TALEN (for transcription activator-like effector nucleases), which is similar to the more widely publicized CRISPR/Cas9, to delete part of a chicken gene called DDX4 that is related to fertility. Hens with this modification did not produce eggs but were healthy in all other ways.

Continue reading “Genetically-engineered hens produce birds of a different feather” »

Mantas from CellAge picks a winner for the iPhone Raffle Reward! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe:
►Reddit AMA: https://www.reddit.com/r/Futurology/comments/5hfmsl/cellage_…ells_with/

Our society has never aged more rapidly – one of the most visible symptoms of the changing demographics is the exponential increase in the incidence of age-related diseases, including cancer, cardiovascular diseases and osteoarthritis. Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030. Similar trends are clearly visible in other age-related diseases such as cardiovascular disease. Few effective treatments addressing these challenges are currently available and most of them focus on a single disease rather than adopting a more holistic approach to aging.

Continue reading “CellAge Campaign: iPhone Reward Raffle Draw” »

Cool story!

Biohackers push back as the scientific establishment charts a course through the ethics of genetic interference.

For those interested in life extension and bionic / cyborg type enhancements, this CMU Robotics Institute Seminar gives an overview of the background and current developments in artificial vision. José Alain Sahel MD is a world leading ophthalmologist with a lengthy bio and numerous honors and appointments.

In the future, if you’re going blind, these sight restoration technologies may be used to remediate your vision loss.

Three major ideas are covered. 1) Implanting arrays of tiny 3-color LEDs under a failed retina to stimulate still-okay cells, and 2) using gene therapy to express a novel photoreceptor, borrowed from algae, to restore a form of sight to failed cells. These can be done together. Lots of studies in mice, primates, and humans. Some coverage is also given to 3) directly implanting electronics in the brain to send complete images to vision centers, but this is still at an early stage.

Continue reading “Artificial Vision, Artificial Retina, Optogenetics, José Alain Sahel MD, CMU RI Seminar” »

Scientists from Harvard University plan to create a mammoth hybrid. They will splice mammoth DNA preserved in Siberian ice with Asian elephant DNA and grow the hybrid in an artificial womb.

In a controversial move, a senior US scientific committee has given the green light to one of the most contentious forms of genome editing: where genetic changes made to human embryos will then be inherited by following generations.

For the first time, a panel of experts from two of the most recognised scientific institutions in the US has advised that this process – called germline editing – should be seriously considered as an option in the future, and not outright prohibited.

It’s a considerably more positive tone than the assessment of an international summit of scientists in December 2015, which declared that it would be “irresponsible to proceed” with germline editing unless safety issues and social consensus could be satisfied.

Continue reading “US Scientists Have Cautiously Backed Permanent Gene Editing in Humans” »

While the recent cases of Ebola and Zika contributed to an emphasis on research, response, and policy related to EIDs, the meeting also had presentations on emerging biotechnologies. Of particular note was the Synthetic Biology panel, which focused on the current state of synthetic biology, its use in the health security defense enterprise, and the policy conundrums that need to be addressed.

Synthetic Biology – Complexity through Simplification

The first presenter, Dr. Christopher Voigt of the Synthetic Biology Center at MIT, noted that synthetic biology was the application of engineering principles to biological systems. The end goal of this bioengineering framework is to leverage ever-increasing computer capabilities to simplify both the designing and writing of genomic sequences. Further simplification would then allow for the creation of more complex systems.

Continue reading “The Biotechnological Wild West: The Good, the Bad, and the Underknown of Synthetic Biology” »

CRISPR/Cas9, a powerful gene editing technique that has already been used in a human, is thought by many as a “cut and paste” for DNA in living organisms. While in a sense that is what happens, delivering the ribonucleoprotein that does the genetic editing and the RNA that hones in on the target, into the cellular nucleus without being damaged is a challenge. That is why the efficiency of successful edits remains very low. Researchers at University of Massachusetts Amherst have now come up with nanoparticles that protect the protein and RNA as they’re brought to their work site.

The nanoparticles are engineered around their cargo and have shown a 90% success rate of getting the cargo into the nucleus, and a 30% editing efficiency, which is “remarkable” according to the researchers. So far the team has tested their technique on cultured cells, but they’re already working on trying the same in laboratory animals. As part of their research, they developed a novel way of tracking the Cas9 protein inside the cells, something that will certainly help other scientists in this area.

“By finely tuning the interactions between engineered Cas9En protein and nanoparticles, we were able to construct these delivery vectors. The vectors carrying the Cas9 protein and sgRNA come into contact with the cell membrane, fuse, and release the Cas9:sgRNA directly into the cell cytoplasm,” in a statement said Vincent Rotello, lead author of the study in ACS Nano. “Cas9 protein also has a nuclear guiding sequence that ushers the complex into the destination nucleus. The key is to tweak the Cas9 protein,” he adds. “We have delivered this Cas9 protein and sgRNA pair into the cell nucleus without getting it trapped on its way. We have watched the delivery process live in real time using sophisticated microscopy.”

Continue reading “Nanoparticles Deliver CRISPR/Cas9 Genetic Editor Safely Into Cells” »